What is Stemgent?
Stemgent operates at the intersection of biotechnology and advanced cellular research, providing essential reagents and innovative technology solutions to the global scientific community. By collaborating with world-renowned stem cell researchers, the company simplifies complex cellular reprogramming workflows, effectively bridging the gap between laboratory discovery and practical application. Its market position is defined by a commitment to high-quality, reliable products that support the advancement of regenerative medicine and therapeutic development. As a key supplier to researchers worldwide, Stemgent remains a pivotal entity in the life sciences supply chain, facilitating breakthroughs that require precision-engineered biological tools.
How much funding has Stemgent raised?
Stemgent has raised a total of $40.8M across 5 funding rounds:
Series A
$6.5M
Series B
$14M
Other Financing Round
$2.7M
Private Equity
$6.3M
Private Equity
$11.3M
Series A (2008): $6.5M with participation from Morgenthaler Private Equity and HealthCare Ventures
Series B (2009): $14M led by Frazier Healthcare Partners and Morgenthaler Private Equity
Other Financing Round (2009): $2.7M supported by Morgenthaler Private Equity and HealthCare Ventures
Private Equity (2012): $6.3M featuring HealthCare Ventures LLC
Private Equity (2012): $11.3M backed by HealthCare Ventures LLC
Key Investors in Stemgent
HealthCare Ventures LLC
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
Morgenthaler Private Equity
Morgenthaler is a premier venture capital and private equity firm with over 40 years of experience in creating valuable companies, specializing in the Information Technology and Life Sciences sectors.
Frazier Healthcare Partners
Frazier Healthcare Partners is a prominent investment firm focused on the healthcare industry, providing capital to companies that drive innovation in biopharmaceuticals and medical technology.
What's next for Stemgent?
With the support of its latest strategic investment, Stemgent is well-positioned to scale its operations and expand its product portfolio to meet the evolving demands of the biotech industry. The company is expected to leverage this capital to enhance its R&D capabilities, focusing on the next generation of cellular reprogramming tools that promise to streamline research timelines. Furthermore, the firm will likely prioritize global market penetration, ensuring that its innovative reagents are accessible to a broader range of academic and commercial institutions. This phase of growth is critical for Stemgent as it seeks to maintain its competitive edge in a rapidly advancing field, ultimately driving long-term value for its stakeholders and the broader scientific community.
See full Stemgent company page
